Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Intelgenx Technologies Corp
(OP:
IGXT
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intelgenx Technologies Corp
< Previous
1
2
3
4
Next >
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q1 2024
May 15, 2024
Intelgenx Technologies just reported results for the first quarter of 2024.
Via
InvestorPlace
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023
March 21, 2024
Intelgenx Technologies just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?
August 14, 2023
IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the...
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
FDA Gives Nod To IntelGenx's Migraine Solution As Revenues Plunge 32%; Q1 Results Report
May 11, 2023
IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same
Via
Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?
March 30, 2023
Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show:
Via
Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 30, 2023
Via
Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
January 27, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
January 26, 2023
Via
Benzinga
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
January 25, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
January 24, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
January 19, 2023
Via
Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
January 16, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
January 13, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 12, 2023
Via
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche
Via
Benzinga
IntelGenx Reports Q3 2022 Financial Results, Management Anticipates Psychedelics Trials In 2023
November 10, 2022
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) reported its financial results late Thursday for the third quarter that ended September 30, 2022.
Via
Benzinga
New Oral Film Tech Improving Cannabinoid Onset Seeks Patent Protection
November 03, 2022
Pharmaceutical films leader IntelGenx Corp. (OTCQB: IGXT) filed a provisional patent application with the U.S.
Via
Benzinga
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
October 25, 2022
Drug delivery company IntelGenx Corp.
Via
Benzinga
Short Volatility Alert: IntelGenx Technologies Corp.
October 04, 2022
On Monday, shares of IntelGenx Technologies Corp. (OTC: IGXT) experienced volatile short activity. After the activity, the stock price went up +7.69% to $0.13. The overall sentiment for IGXT has been...
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
August 01, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 4.95% at $0.34
Via
Benzinga
Psychedelic Stock Gainers And Losers From July 29, 2022
July 29, 2022
GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 11.30% at $0.22
Via
Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
June 09, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13
Via
Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
June 08, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
June 07, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
June 06, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36
Via
Benzinga
Psychedelic Stock Gainers And Losers From June 3, 2022
June 03, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.